XILLIX FDA APPROVED Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XILLIX FDA APPROVED

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gari Rolfe who wrote (274)	6/11/1998 1:05:00 AM
From: Garry K.	Read Replies (1) of 572

I contacted Laurie at IR to pose some questions on her about the recent erosion in share price. Management is somewhat puzzled about the share price, especially since the very positive news about the Miravant deal was released. As you may have noticed, volume increased somewhat a couple of days ago. Laurie believes this may have been an institution getting out of the stock. I personally do not view this as much of a concern, for the volume was not that high. As far as company progress, the fundamentals of the company are getting stronger: sales of LIFE-Lung are progressing well, new product developments are on track and the alliance with Olympus remains strong. We also have an additional $7.2million in additional cash from the Miravant deal, as well as a future stream of drug royalties. Laurie also mentioned that four analysts have been following the company, and all had positive comments on the Miravant announcement. Hope this provides some insight. Comments?? Garry

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next